Cormorant Asset Management, LP Incyte Corp Transaction History

Cormorant Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $2.21 Million - $2.66 Million	-30,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $14.1 Million - $19.5 Million	-221,335 Reduced 88.06%	30,000 $2.58 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $506,902 - $606,030	-8,665 Reduced 3.33%	251,335 $16 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $3.71 Million - $4.45 Million	60,000 Added 30.0%	260,000 $18 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $12.2 Million - $16.8 Million	200,000 New	200,000 $13.4 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.